Vabicaserin (codenamed SCA-136) is an investigational antipsychotic and anorectic that was under development by Wyeth. As of 2010, it is no longer in clinical trials for the treatment of psychosis. It was also under investigation as an antidepressant, but this indication was dropped as well. Vabicaserin acts as a selective 5-HT2C receptor full agonist (Ki = 3 nM; EC50 = 8 nM; IA = 100% (relative to 5-HT)) and 5-HT2B receptor antagonist (IC50 = 29 nM). It is also a very weak antagonist at the 5-HT2A receptor (IC50 = 1,650 nM), though this action is not clinically significant. By activating 5-HT2C receptors, vabicaserin inhibits dopamine release in the mesolimbic pathway, likely underlying its efficacy in alleviating positive symptoms of schizophrenia, and increases acetylcholine and glutamate levels in the prefrontal cortex, suggesting benefits against cognitive symptoms as well.
See also List of investigational antipsychotics List of investigational bipolar disorder drugs Bexicaserin BMB-101 Lorcaserin WAY-163909
References


